Kaufman DS - Search Results

1

CHMP2A regulates tumor sensitivity to natural killer cell-mediated cytotoxicity.

Bernareggi D, Xie Q, Prager BC, Yun J, Cruz LS, Pham TV, Kim W, Lee X, Coffey M, Zalfa C, Azmoon P, Zhu H, Tamayo P, Rich JN, Kaufman DS. Bernareggi D, et al. Among authors: kaufman ds. Nat Commun. 2022 Apr 7;13(1):1899. doi: 10.1038/s41467-022-29469-0. Nat Commun. 2022. PMID: 35393416 Free PMC article.

2

Mouse Xenograft Model for Intraperitoneal Administration of NK Cell Immunotherapy for Ovarian Cancer.

Hermanson DL, Bendzick L, Kaufman DS. Hermanson DL, et al. Among authors: kaufman ds. Methods Mol Biol. 2016;1441:277-84. doi: 10.1007/978-1-4939-3684-7_23. Methods Mol Biol. 2016. PMID: 27177674

3

Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy.

Zhu H, Lai YS, Li Y, Blum RH, Kaufman DS. Zhu H, et al. Among authors: kaufman ds. Stem Cells. 2018 Feb;36(2):134-145. doi: 10.1002/stem.2754. Epub 2018 Jan 3. Stem Cells. 2018. PMID: 29235195 Free PMC article. Review.

4

Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity.

Li Y, Hermanson DL, Moriarity BS, Kaufman DS. Li Y, et al. Among authors: kaufman ds. Cell Stem Cell. 2018 Aug 2;23(2):181-192.e5. doi: 10.1016/j.stem.2018.06.002. Epub 2018 Jun 28. Cell Stem Cell. 2018. PMID: 30082067 Free PMC article.

5

Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.

Saetersmoen ML, Hammer Q, Valamehr B, Kaufman DS, Malmberg KJ. Saetersmoen ML, et al. Among authors: kaufman ds. Semin Immunopathol. 2019 Jan;41(1):59-68. doi: 10.1007/s00281-018-0721-x. Epub 2018 Oct 25. Semin Immunopathol. 2019. PMID: 30361801 Review.

6

Development of innate immune cells from human pluripotent stem cells.

Bernareggi D, Pouyanfard S, Kaufman DS. Bernareggi D, et al. Among authors: kaufman ds. Exp Hematol. 2019 Mar;71:13-23. doi: 10.1016/j.exphem.2018.12.005. Epub 2019 Jan 4. Exp Hematol. 2019. PMID: 30611869 Free PMC article. Review.

7

An Improved Method to Produce Clinical-Scale Natural Killer Cells from Human Pluripotent Stem Cells.

Zhu H, Kaufman DS. Zhu H, et al. Among authors: kaufman ds. Methods Mol Biol. 2019;2048:107-119. doi: 10.1007/978-1-4939-9728-2_12. Methods Mol Biol. 2019. PMID: 31396935

8

Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity.

Zhu H, Blum RH, Bjordahl R, Gaidarova S, Rogers P, Lee TT, Abujarour R, Bonello GB, Wu J, Tsai PF, Miller JS, Walcheck B, Valamehr B, Kaufman DS. Zhu H, et al. Among authors: kaufman ds. Blood. 2020 Feb 6;135(6):399-410. doi: 10.1182/blood.2019000621. Blood. 2020. PMID: 31856277 Free PMC article.

9

Metabolic Reprograming via Deletion of CISH in Human iPSC-Derived NK Cells Promotes In Vivo Persistence and Enhances Anti-tumor Activity.

Zhu H, Blum RH, Bernareggi D, Ask EH, Wu Z, Hoel HJ, Meng Z, Wu C, Guan KL, Malmberg KJ, Kaufman DS. Zhu H, et al. Among authors: kaufman ds. Cell Stem Cell. 2020 Aug 6;27(2):224-237.e6. doi: 10.1016/j.stem.2020.05.008. Epub 2020 Jun 11. Cell Stem Cell. 2020. PMID: 32531207 Free PMC article.

10

iPSC-derived NK cells maintain high cytotoxicity and enhance in vivo tumor control in concert with T cells and anti-PD-1 therapy.

Cichocki F, Bjordahl R, Gaidarova S, Mahmood S, Abujarour R, Wang H, Tuininga K, Felices M, Davis ZB, Bendzick L, Clarke R, Stokely L, Rogers P, Ge M, Robinson M, Rezner B, Robbins DL, Lee TT, Kaufman DS, Blazar BR, Valamehr B, Miller JS. Cichocki F, et al. Among authors: kaufman ds. Sci Transl Med. 2020 Nov 4;12(568):eaaz5618. doi: 10.1126/scitranslmed.aaz5618. Sci Transl Med. 2020. PMID: 33148626 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

213 results

Search Page